CA2963692A1 - Bispecific antibodies against cd3epsilon and ror1 - Google Patents

Bispecific antibodies against cd3epsilon and ror1 Download PDF

Info

Publication number
CA2963692A1
CA2963692A1 CA2963692A CA2963692A CA2963692A1 CA 2963692 A1 CA2963692 A1 CA 2963692A1 CA 2963692 A CA2963692 A CA 2963692A CA 2963692 A CA2963692 A CA 2963692A CA 2963692 A1 CA2963692 A1 CA 2963692A1
Authority
CA
Canada
Prior art keywords
ror1
antibody
fab
cells
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2963692A
Other languages
English (en)
French (fr)
Inventor
Minh Diem Vu
Klaus Strein
Oliver Ast
Tanja FAUTI
Anne Freimoser-Grundschober
Ralf Hosse
Christian Klein
Ekkehard Moessner
Samuel Moser
Ramona MURR
Pablo Umana
Sabine JUNG-IMHOF
Stefan Klostermann
Michael MOLHOJ
Joerg Regula
Wolfgang Schaefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Engmab SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engmab SARL filed Critical Engmab SARL
Publication of CA2963692A1 publication Critical patent/CA2963692A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2963692A 2014-10-09 2015-10-08 Bispecific antibodies against cd3epsilon and ror1 Abandoned CA2963692A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14188378 2014-10-09
EP14188378.5 2014-10-09
EP14188727 2014-10-14
EP14188727.3 2014-10-14
PCT/EP2015/073308 WO2016055592A1 (en) 2014-10-09 2015-10-08 Bispecific antibodies against cd3epsilon and ror1

Publications (1)

Publication Number Publication Date
CA2963692A1 true CA2963692A1 (en) 2016-04-14

Family

ID=54291292

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2963692A Abandoned CA2963692A1 (en) 2014-10-09 2015-10-08 Bispecific antibodies against cd3epsilon and ror1

Country Status (7)

Country Link
US (1) US11952421B2 (enExample)
EP (1) EP3204415B1 (enExample)
JP (1) JP6708635B2 (enExample)
AU (1) AU2015329965A1 (enExample)
CA (1) CA2963692A1 (enExample)
ES (1) ES2850325T3 (enExample)
WO (1) WO2016055592A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
CN107586340B (zh) 2011-08-23 2022-01-21 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
BR112015007120A2 (pt) 2012-10-08 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
UA119320C2 (uk) 2013-02-26 2019-06-10 Рош Глікарт Аг Активуюча т-клітини біспецифічна антигензв'язувальна молекула
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
SMT202400235T1 (it) 2014-08-04 2024-07-09 Hoffmann La Roche Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
AU2015329965A1 (en) * 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
RU2753902C2 (ru) 2014-11-20 2021-08-24 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3150636A1 (en) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
HK1254836A1 (zh) 2015-10-30 2019-07-26 Nbe-Therapeutics Ag 抗-ror1抗体
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
PL3433280T3 (pl) 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
AU2018289581C1 (en) 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
EP3645050A4 (en) * 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
US20210139579A1 (en) * 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
TWI820041B (zh) * 2017-09-21 2023-11-01 中國大陸商上海藥明生物技術有限公司 新型抗CD3ε抗體
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
CN118772287A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
CN112384533A (zh) 2018-04-18 2021-02-19 埃克塞里艾克西斯公司 抗-ror抗体构建体
CN109580504B (zh) * 2018-10-19 2021-10-26 东软威特曼生物科技(南京)有限公司 一种脂蛋白胆固醇测定试剂及试剂盒
CA3139111A1 (en) * 2019-05-23 2020-11-26 VelosBio Inc. Anti-ror1/anti-cd3 bispecific binding molecules
US20220372071A1 (en) * 2019-11-07 2022-11-24 Amgen Inc. High salt washes during cation exchange chromatography to remove product-related impurities
MX2022005593A (es) * 2019-11-07 2022-06-09 Amgen Inc Acondicionamiento de la carga con salinidad elevada durante la cromatografia de intercambio cationico para eliminar impurezas relacionadas del producto.
CA3166286A1 (en) 2020-02-07 2021-08-12 Jeffry D. Watkins Anti-ror1 antibodies and compositions
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
TWI907489B (zh) * 2020-08-24 2025-12-11 香港商岸邁生物科技（香港）有限公司 抗ｒｏｒ１抗體及相關雙特異性結合蛋白
KR20230166075A (ko) 2021-02-02 2023-12-06 누맙 세러퓨틱스 아게 Ror1 및 cd3에 대한 특이성을 가지는 다중 특이적 항체
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4423145A1 (en) 2021-10-28 2024-09-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
IL101661A (en) 1991-04-23 1998-02-08 Regeneron Pharma Method for detecting, identifying or measuring agents having neurotrophin activity
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
IL113252A0 (en) 1994-04-04 1995-07-31 Regeneration Pharmaceuticals I Eph receptors binding ligands
CA2208783C (en) 1994-12-30 2010-09-28 Planet Biotechnology, Inc. Methods for producing immunoglobulins containing protection proteins in plants and their use
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
DK1049787T3 (da) 1998-01-23 2005-04-04 Vlaams Interuniv Inst Biotech Antistofderivater med flere anvendelsesmuligheder
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
DE60127143T2 (de) 2001-11-14 2007-11-15 Affimed Therapeutics Ag Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
US8932603B2 (en) 2003-02-25 2015-01-13 Vaccibody As Modified antibody
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
JP2007508801A (ja) 2003-10-24 2007-04-12 エスバテック・アーゲー 受容体チロシンキナーゼ阻害剤の同定および／または確認のための方法
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
AU2005233564A1 (en) 2004-04-06 2005-10-27 The Regents Of The University Of California Orphan receptor tyrosine kinase as a target in breast cancer
WO2005118629A1 (en) 2004-06-02 2005-12-15 Diatech Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
CA2599265A1 (en) 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
RU2008110060A (ru) 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Сконструированные антитела с каркасными участками приматов нового света
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2008103849A2 (en) 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
WO2007051077A2 (en) 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
EP2007808A4 (en) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US20100021379A1 (en) 2006-06-29 2010-01-28 The Regents Of The University Of California Chemical Antibodies for Immunotherapy and Imaging
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2316491B1 (en) 2008-07-18 2016-10-12 National University Corporation Nagoya University Cell proliferation inhibitor
RU2547600C2 (ru) * 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
WO2010063785A2 (en) 2008-12-03 2010-06-10 Genmab A/S Antibody variants having modifications in the constant region
EP2421899B1 (en) 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
EP2496605A1 (en) * 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
CN102712695B (zh) 2009-12-18 2015-01-21 堪瑟拉公司 能够诱导细胞死亡的ror1生物抑制剂
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
CN102330723A (zh) 2010-07-13 2012-01-25 新秩序投资119股份有限公司 管配件
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
WO2012075158A1 (en) * 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US9890218B2 (en) 2011-06-30 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
PH12013502531A1 (en) * 2011-08-23 2014-01-20 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN107586340B (zh) 2011-08-23 2022-01-21 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
EP2787078B1 (en) 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
HRP20201004T1 (hr) 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
KR20150013188A (ko) 2012-05-24 2015-02-04 에프. 호프만-라 로슈 아게 다중특이적 항체
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
BR112015007120A2 (pt) * 2012-10-08 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
UA119320C2 (uk) 2013-02-26 2019-06-10 Рош Глікарт Аг Активуюча т-клітини біспецифічна антигензв'язувальна молекула
US10351626B2 (en) 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
DK3107938T3 (da) * 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
SMT202400235T1 (it) * 2014-08-04 2024-07-09 Hoffmann La Roche Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CA2960756C (en) * 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
EP3670535A1 (en) 2015-08-03 2020-06-24 EngMab Sàrl Monoclonal antibodies against bcma
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
WO2020219978A1 (en) 2019-04-25 2020-10-29 Celgene Corporation Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies
CA3160137A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company Methods of treatment with antibodies against bcma and cd3
WO2021092060A1 (en) 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment
MX2022009784A (es) 2020-02-12 2022-09-09 Bristol Myers Squibb Co Terapia anti-bcma en trastornos autoinmunes.
US20230172923A1 (en) 2020-04-30 2023-06-08 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events

Also Published As

Publication number Publication date
ES2850325T3 (es) 2021-08-27
JP6708635B2 (ja) 2020-06-10
AU2015329965A1 (en) 2017-04-27
EP3204415B1 (en) 2020-06-17
EP3204415A1 (en) 2017-08-16
WO2016055592A1 (en) 2016-04-14
US11952421B2 (en) 2024-04-09
US20170306018A1 (en) 2017-10-26
JP2018502050A (ja) 2018-01-25

Similar Documents

Publication Publication Date Title
EP3204415B1 (en) Bispecific antibodies against cd3epsilon and ror1
US20170306044A1 (en) Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
US20200255521A1 (en) Bispecific antibodies against cd3epsilon and ror1
DK2982694T3 (en) Bispecific antibodies against CD3epsilon and BCMA
JP6822849B2 (ja) 多重特異的ＮＫｐ４６結合タンパク質
US20170327579A1 (en) Bispecific antibodies against cd3epsilon and bcma
EP3747905A1 (en) Common light chains and methods of use
EP2953974A1 (en) Bispecific antibodies against cd3epsilon and bcma
WO2024251154A9 (zh) 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

FZDE Discontinued

Effective date: 20230127

FZDE Discontinued

Effective date: 20230127